TB-500: what the research shows
A small piece of a natural repair protein. Popular for recovery, but barely tested in people.
Also known as Thymosin beta-4 fragment
At a glance
Not approved, and banned in sport by WADA. In 2026 the FDA took it off its “do not compound” list, but that is not an approval.
Step 1 of 5: Cells
Step 2 of 5: Animals
Step 3 of 5: Small human studies
Step 4 of 5: Large trials
Step 5 of 5: Approved medicine
What is TB-500?
TB-500 is a short, lab-made piece of thymosin beta-4, a protein found in almost every cell. Thymosin beta-4 helps cells move and build their inner “scaffolding”.
How does TB-500 work?
In lab and animal studies, thymosin beta-4 helps cells travel to wounds and supports new blood-vessel growth. Whether the small TB-500 fragment does the same in people hasn’t been shown.
What does the research show?
- The full-length protein, thymosin beta-4, has been tested in small human trials, for example as eye drops for dry eye and as a gel for slow-healing leg ulcers, with early or mixed results.
- There are no good human trials of the TB-500 fragment itself.
- FDA advisers reviewed TB-500 for wound healing in July 2026 as a possible compounding ingredient.
Known risks and side effects
- Safety in people is unknown.
- Products sold online are unregulated, so quality varies.
Is TB-500 approved?
Mostly studied in cells and animals, with little or no proper testing in people.
Not approved, and banned in sport by WADA. In 2026 the FDA took it off its “do not compound” list, but that is not an approval.
From the community
Watch: TB-500 and related science
Start with the compound discussion, then use the background lesson to understand its biology. Each card explains its connection. Recordings may predate later findings or regulatory changes.
Pain Specialists Australia
BPC-157 for pain: what the evidence actually says
Two pain specialists weigh the evidence and the risks of BPC-157, TB-500, ARA-290, MOTS-c and GHK-Cu, including contamination of products sold online.
Dr Nick Christelis and Dr Bradley Lewinsohn, specialist pain medicine physicians (FFPMANZCA)
Discusses the compound
Two specialist pain physicians review the evidence for BPC-157 (from 16:08), TB-500 (24:04), ARA-290 (4:54), MOTS-c (25:51) and GHK-Cu (24:56), and the risks of unregulated products.
U.S. Food and Drug Administration
FDA peptide compounding meeting: July 23, 2026
Full meeting covering BPC-157, KPV, TB-500 and MOTS-c. Advisory discussion is not drug approval.
Official FDA advisory committee recording
Official regulatory recording
The original July 23, 2026 FDA discussion of BPC-157, KPV, TB-500 and MOTS-c; it documents an advisory review.
Khan Academy
Phagocytes and innate immunity
How part of the immune system responds to threats and contributes to inflammation.
Immune-system biology education
Related biology
Background on immune cells and inflammation for understanding TB-500. It does not demonstrate benefits of this compound or formulation.
Sources and references
- Thymosin β4: a multi-functional regenerative peptideGoldstein et al. · Expert Opinion on Biological Therapy · 2012
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trialSosne et al. · Clinical Ophthalmology · 2015
- FDA Pharmacy Compounding Advisory Committee, July 23–24, 2026US Food and Drug Administration · meeting page
VETUD Learn explains published research in plain language. It is general information, not medical advice. Talk to a doctor before starting, stopping or changing any treatment.
In the research shop
Check the catalog for related laboratory research materials. These products are separate from the approved medicines and clinical trial formulations discussed here.
Checking regional availability…
